7.60
CorMedix Inc stock is traded at $7.60, with a volume of 1.18M.
It is down -3.43% in the last 24 hours and down -3.18% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$7.87
Open:
$8
24h Volume:
1.18M
Relative Volume:
0.93
Market Cap:
$596.23M
Revenue:
$400.05M
Net Income/Loss:
$181.01M
P/E Ratio:
3.6203
EPS:
2.0993
Net Cash Flow:
$194.58M
1W Performance:
-2.31%
1M Performance:
-3.18%
6M Performance:
-1.94%
1Y Performance:
-33.86%
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CRMD
CorMedix Inc
|
7.60 | 617.42M | 400.05M | 181.01M | 194.58M | 2.0993 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
CorMedix Inc (CRMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRMD|CorMedix Inc|Price:8.020|Chg%:+0.150 - TradingKey
CorMedix Inc (CRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
ETFs Investing in CorMedix Inc. Stocks - TradingView
CRMD|CorMedix Inc|Price:7.870|Chg%:-0.180 - TradingKey
CorMedix Inc. Revenue Breakdown – LS:A2PF3G - TradingView
CorMedix Inc (CRMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
CorMedix Inc. Revenue Breakdown – NASDAQ:CRMD - TradingView
(CRMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
CorMedix Inc (CRMD) Institutional Confidence - TradingKey
CRMD|CorMedix Inc|Price:8.060|Chg%:+0.010 - TradingKey
CorMedix Inc (CRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CorMedix (NASDAQ:CRMD) Stock Price Down 5.9%Time to Sell? - MarketBeat
CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
CorMedix Inc. (CRMD) Advances 1.57% as Stock Approaches Key Resistance at $8.84Money Flow - dars.gov.et
CRMD6219746 Bond Risk Profile - TradingView
CRMD6219746 Bond Coupon Profile — Rate & Payments - TradingView
CRMD6219746 Bond Profile — Key Metrics - TradingView
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge - Stocktwits
Enterprise value to revenue forward of CorMedix Inc. – NASDAQ:CRMD - TradingView
Enterprise value to revenue forward of CorMedix Inc. – LSX:A2PF3G - TradingView
Private Advisor Group LLC Buys 126,131 Shares of CorMedix Inc $CRMD - MarketBeat
RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
RBC Capital Trims CorMedix Price Target to $13 From $14, Maintains Outperform Rating - marketscreener.com
CRMDCorMedix Inc Volatility & Greeks - Finviz
Cormedix Restructures Leadership, Expands Operating and Commercial Role - The Globe and Mail
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer - Moomoo
[8-K] CorMedix Inc. Reports Material Event - Stock Titan
Lobbying Update: $380,000 of CORMEDIX INC. lobbying was just disclosed - Quiver Quantitative
Tranche Update on CorMedix Inc.'s Equity Buyback Plan announced on February 2, 2026. - marketscreener.com
Liquidity Mapping Around (CRMD) Price Events - Stock Traders Daily
CRMD,PEP Revenue Breakdown - Finviz
CORMEDIX INC. Files 8-K: Company Details, Stock Info & SEC Filing Summary for June 25, 2026 - Minichart
CorMedix (NASDAQ: CRMD) replaces CBIZ with Ernst & Young as auditor - Stock Titan
CRMD's Growth Story Expands Beyond DefenCath Into New Trends - Yahoo Finance
Is CRMD Stock a Buy Now After Strong Growth and New Risks? - Yahoo Finance
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path - TradingView
CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
CorMedix Inc.(NasdaqGM: CRMD) dropped from Russell 2500 Growth Benchmark - marketscreener.com
CorMedix Inc. (CRMD) Slips 2.74% as Stock Tests Support Near $7.25Volatility Smirk - dars.gov.et
CorMedix Inc.(NasdaqGM: CRMD) added to Russell 2000 Value Benchmark - marketscreener.com
CorMedix Inc.(NasdaqGM: CRMD) added to Russell Microcap Value Benchmark Index - marketscreener.com
CorMedix Inc.(NasdaqGM: CRMD) dropped from Russell 2000 Growth Benchmark - marketscreener.com
CorMedix Inc.(NasdaqGM: CRMD) dropped from Russell 3000E Growth Benchmark - marketscreener.com
CorMedix Inc.(NasdaqGM: CRMD) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits
CorMedix Inc.(NasdaqGM: CRMD) added to Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBIT forward of CorMedix Inc. – NASDAQ:CRMD - TradingView
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):